JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, Crizotinib, unlike Imatinib, can effectively overcome the TME-mediated chemoresistance in CML cells, which was attributed to the ability of Crizotinib to inhibit JAK2 activity [21].